急性冠脉综合征急诊快速诊治指南(2019)

doi:10.3969/j.issn.1002-1949.2019.04.001

摘要
图/表
参考文献(47)
相关文章 (15)

全文: PDF (1044 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要急性冠脉综合征（acute coronary syndromes，ACS）是指冠状动脉内不稳定的粥样硬化斑块破裂或糜烂继发新鲜血栓形成所导致的心脏急性缺血综合征，涵盖了ST段抬高型心肌梗死（ST elevation myocardial infarction, STEMI）、非ST段抬高型心肌梗死（non ST elevation myocardial infarction, NSTEMI）和不稳定性心绞痛（unstable angina， UA），其中NSTEMI与UA合称为非ST段抬高型急性冠脉综合征（NSTE-ACS）。ACS的发病率在我国依然呈逐年增加的态势，而且绝大多数ACS患者首诊于急诊科。2016年4月，中国医师协会急诊医师分会邀请中华医学会心血管病学分会、中华医学会检验医学分会、中华医学电子音像出版社共同制定并发布了《急性冠脉综合征急诊快速诊疗指南》，对于缩短ACS患者从首次医疗接触（first medical contact, FMC）到治疗的时间、规范ACS的急诊诊治流程尤其强化包括静脉溶栓在内的早期再灌注治疗，起到了积极的指导作用。三年来，ACS的诊治又取得了重要进展，为保证学术的先进性，并在实践上与国内外新的指南接轨，中国医师协会急诊医师分会同国家卫健委能力建设与继续教育中心急诊学专家委员会、中国医疗保健国际交流促进会急诊急救分会组织会同相关专家对2016年的《急性冠脉综合征急诊快速诊疗指南》进行修订，发布《急性冠脉综合征急诊快速诊治指南（2019）》，进一步推进ACS在急诊科（含院前急救）与相关学科的科学化管理。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	中国医师协会急诊医师分会
	国家卫健委能力建设与继续教育中心急诊学专家委员会
	中国医疗保健国际交流促进会急诊急救分会

通讯作者: 张新超（北京医院国家老年医学中心急诊科，E-mail: xinchaoz@163.com），于学忠（北京协和医院急诊科，E-mail: yxz@pumch.cn），陈凤英（内蒙古医科大学附属医院急诊科，E-mail: fychen627@sohu.com），朱华栋（北京协和医院急诊科，E-mail: zhuhuadong1970@126.com）

引用本文:

中国医师协会急诊医师分会，国家卫健委能力建设与继续教育中心急诊学专家委员会，中国医疗保健国际交流促进会急诊急救分会. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 中国急救医学, 2019, 39(4): 301-308.

链接本文:

http://www.cnemergency.org.cn/CN/10.3969/j.issn.1002-1949.2019.04.001 或 http://www.cnemergency.org.cn/CN/Y2019/V39/I4/301

［1］中国医师协会急诊医师分会，中华医学会心血管病学分会，中华医学会检验医学分会. 急性冠脉综合征急诊快速诊疗指南［J］. 中国急救医学，2016, 36(3): 207-214. ［2］中华医学会心血管病学分会，中华医学会检验医学分会. 高敏感方法检测心肌肌钙蛋白临床应用中国专家共识(2014)［J］. 中华内科杂志, 2015, 54(10):899-904. ［3］Mueller C, Giannitsis E, Christ M, et al. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin T［J］. Ann Emerg Med, 2016，Jan 8. pii: S0196-0644(15)01501-2.  ［4］Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T［J］. Arch Intern Med, 2012, 172(16):1211-1218. ［5］中华医学会心血管病学分会，中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南［J］. 中华心血管病杂志, 2015, 43(5):380-393. ［6］Nabi F, Chang SM, Xu J, et al. Assessing risk in acute chest pain: The value of stress myocardial perfusion imaging in patients admitted through the emergency department［J］. J Nucl Cardiol, 2012, 19(2):233-243. ［7］Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials［J］. J Am Coll Cardiol, 2013, 61(8):880-892. ［8］Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)［J］. Eur Heart J, 2016, 37(3):267-315. ［9］Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk Derivation, external validation and outcomes using the updated GRACE risk score［J］. BMJ Open, 2014, 4(2):e4425. ［10］Abu-Assi E, Raposeiras-Roubin S, Lear P, et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome［J］. Eur Heart J Acute Cardiovasc Care, 2012, 1(3):222-231. ［11］Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes［J］. N Engl J Med, 2009, 361(11):1045-1057. ［12］Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis［J］. Circulation, 2010, 122(21):2131-2141. ［13］Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial［J］. Eur Heart J, 2014, 35(31):2083-2093. ［14］Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)［J］. Eur Heart J, 2018, 39(3):213-260.  ［15］Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial［J］. JAMA Cardiol, 2018,3(5):391-399. ［16］Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)［J］. Eur Heart J, 2018, 39(2):119-177. ［17］Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update［J］. Circulation, 2012, 125(2):375-380. ［18］DE Luca G, Bellandi F, Huber K, et al. Early glycoprotein Ⅱb-Ⅲa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient′s data meta-analysis［J］. J Thromb Haemost, 2011, 9(12):2361-2370. ［19］Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization［J］. Eur Heart J, 2019, 40(2):87-165. ［20］Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial［J］. JAMA, 2015, 313(13):1336-1346.  ［21］Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial［J］. JAMA, 2006, 295(13):1519-1530.  ［22］Qiao J, Zhang X, Zhang J, et al. Comparison between fondaparinux and low-molecular-weight heparin in patients with acute coronary syndrome: A meta-analysis［J］. Cardiology, 2016, 133(3):163-172.  ［23］Bugiardini R, Cenko E, Ricci B, et al. Comparison of early versus delayed oral beta blockers in acute coronary syndromes and effect on outcomes［J］. Am J Cardiol, 2016, 117(5):760-767.  ［24］Park KL, Goldberg RJ, Anderson FA, et al. Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE)［J］. Am J Med, 2014, 127(6):503-511.  ［25］Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial［J］. Lancet, 2005, 366(9497):1622-1632.  ［26］Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome［J］. Int J Cardiol, 2009, 137(3):246-251.  ［27］Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials［J］. Lancet, 2010, 376(9753):1670-1681. ［28］Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes［J］. N Engl J Med, 2004, 350(15):1495-1504. ［29］Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up［J］. Eur Heart J, 2009, 30(13):1598-1606. ［30］Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase［J］. Circulation, 2011, 124(23):2512-2521. ［31］Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction［J］. N Engl J Med, 2013, 368(15):1379-1387. ［32］Bhatt NS, Solhpour A, Balan P, et al. Comparison of in-hospital outcomes with low-dose fibrinolytic therapy followed by urgent percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of ST-elevation myocardial infarction［J］. Am J Cardiol, 2013, 111(11):1576-1579. ［33］Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis［J］. Eur Heart J, 2010, 31(17):2156-2169. ［34］Shen LH, Wan F, Shen L, et al. Pharmacoinvasive therapy for ST elevation myocardial infarction in China: a pilot study［J］. J Thromb, 2012, 33(1):101-108. ［35］Danchin N, Coste P, Ferrieres J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French registry on acute ST-elevation myocardial infarction(FAST-MI)［J］. Circulation, 2008, 118(3):268-276. ［36］国家卫生计生委合理用药专家委员会, 中国药师协会. 冠心病合理用药指南（第2版）［J］. 中国医学前沿杂志(电子版), 2018, 10(6):1-127.  ［37］Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction［J］. N Engl J Med, 2008, 358(21):2205-2217.  ［38］Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial［J］. Lancet, 2006, 367(9510):569-578.  ［39］Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on district treatment of ST-elevation myocardial infarction)［J］. J Am Coll Cardiol, 2010, 55(2):102-110. ［40］Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction［J］. N Engl J Med, 2009, 360(26):2705-2718. ［41］Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock［J］. JAMA, 2001, 285(2):190-192. ［42］Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial［J］. Lancet, 2008, 371(9612):559-568. ［43］Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction［J］. N Engl J Med, 2005, 353(26):2758-2768. ［44］Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)［J］. Eur Heart J, 2014, 35(37):2541-2619. ［45］Katritsis DG, Siontis GC, Kastrati A, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes［J］. Eur Heart J, 2011, 32(1):32-40. ［46］Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes［J］. N Engl J Med, 2009, 360(21):2165-2175. ［47］中国医师协会急诊医师分会. 中国急性心力衰竭急诊临床实践指南(2017)［J］. 中国急救医学，2017, 37(12): 1063-1074.